China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...
3d
Dupixent approved in China as the first-ever biologic medicine for patients with COPDApproval follows EU approval of Dupixent for adults with ...
Terence Flynn, an analyst from Morgan Stanley, maintained the Buy rating on Regeneron (REGN – Research Report). The associated price ...
REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children ...
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
Dupixent, an interleukin-4 receptor alpha antagonist, is supplied in single-dose prefilled syringes and prefilled pens. The recommended dosage for patients aged 12 years and older with CRSwNP is ...
TARRYTOWN, N.Y. - The U.S. Food and Drug Administration (FDA) has expanded the approval for Dupixent® (dupilumab) to include adolescent patients aged 12 to 17 with inadequately controlled chronic ...
TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...
13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab ...
This is the ninth indication for DUPIXENT ® in Canada and its second in gastroenterology 1 Expanded indication marks second disease for which DUPIXENT ® is approved in children this young in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback